Cell Therapy Advances but Parkinson's Research Still on Shaky Ground
This article was originally published in Start Up
Executive Summary
A trio of recent papers provides encouragement about the use of cell therapy to treat motor symptoms in Parkinson's disease. But the discussions also highlight how much is not known about the origins of Parkinson's disease, and suggest there may be fundamental limitations to any therapy strategy based on restoring dopamine--be it through implanting dopamine neurons or via existing drugs.
You may also be interested in...
Preventing Toxic Effects Of Protein Aggregation In Parkinson’s Disease
Researchers have shown that a new class of small molecule can inhibit assembly of the protein alpha-synuclein into toxic clumps, a hallmark of Parkinson’s disease. Their work supports other ongoing investigations suggesting that the compound may be useful as a neuroprotective agent for treating a range of diseases characterized by the clumping of amyloid proteins, including Alzheimer’s disease, various types of amyloidosis, and prion disease.
Best of the Blog: Start-Up April 2008
"Best of the Blog" is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In May: cell therapy for Parkinson's, the difficulty of SPACs, Roche buys Piramed, and another boost for microRNA.
Best of the Blog: Start-Up April 2008
"Best of the Blog" is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In May: cell therapy for Parkinson's, the difficulty of SPACs, Roche buys Piramed, and another boost for microRNA.